Home Biosimilar Antibodies Immunology & Inflammation CD markers Gatralimab (Anti-CD52)
For research use only. Not for use in humans.

Gatralimab (Anti-CD52)

Synonyms: CD52,He5

Gatralimab (Anti-CD52) is an IgG1 anti-CD52 monoclonal antibody with the potential to treat Symptomatic Osteoarthritis. MW : 145.0 KD.

Gatralimab (Anti-CD52)

Quality Control

Batch: A283001 Purity: 99% Protein concentration: 7.107mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 1
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Gatralimab (Anti-CD52) is an IgG1 anti-CD52 monoclonal antibody with the potential to treat Symptomatic Osteoarthritis. MW : 145.0 KD.
References

Product Details

CAS No. 1826020-80-7
Molecular Weight 145
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02395497 RECRUITING Drug: Tacrolimus Amputation; Wounds and Injuries; Amputation, Traumatic; Urologic Surgical Procedures, Male; Amputation, Traumatic/Surgery; Penis/Transplantation; Penis/Surgery; Penis/Injuries; Congenital Anomaly, Male Genitalia Johns Hopkins University 2014-06 PHASE2; PHASE3
NCT04416984 ACTIVE_NOT_RECRUITING Drug: Fludarabine|Drug: Cyclophosphamide Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma Allogene Therapeutics 2020-05-21 PHASE1; PHASE2
NCT05557903 UNKNOWN Lymphoma, Non-Hodgkin; Lymphoma, T-Cell Lanzhou Institute of Biological Products Co., Ltd 2021-12-20 PHASE1
NCT03240822 WITHDRAWN Drug: Tacrolimus Urologic Injuries; Genital Diseases, Male; Amputation Wake Forest University Health Sciences 2017-01 PHASE1
NCT03939026 COMPLETED Drug: Fludarabine|Drug: Cyclophosphamide Relapsed/Refractory Large B Cell Lymphoma; Relapsed/Refractory Follicular Lymphoma Allogene Therapeutics 2019-05-01 PHASE1
NCT01982175 SUSPENDED B-cell Chronic Lymphocytic Leukemia Shanghai Zhangjiang Biotechnology Limited Company 2011-07 PHASE2

(data from https://clinicaltrials.gov, updated on 2026-07-14)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.